CADL Stock Summary and Trading Ideas (Candel Therapeutics | NASDAQ:CADL)

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Candel Therapeutics trades on the NASDAQ stock market under the symbol CADL.

As of March 3, 2025, CADL stock price declined to $7.91 with 1,109,688 million shares trading.

CADL has a beta of 0.14, meaning it tends to be less sensitive to market movements. CADL has a correlation of 0.00 to the broad based SPY ETF.

CADL has a market cap of $351.80 million. This is considered a Small Cap stock.

In the last 3 years, CADL traded as high as $14.60 and as low as $.66.

The top ETF exchange traded funds that CADL belongs to (by Net Assets): VTI, IWM, VXF, IWO, VFMO.

CADL has outperformed the market in the last year with a return of +365.3%, while the SPY ETF gained +15.2%. In the last 3 month period, CADL beat the market returning +75.4%, while SPY returned -3.0%. However, in the most recent 2 weeks CADL has underperformed the stock market by returning -12.6%, while SPY returned -4.3%.

CADL support price is $8.26 and resistance is $9.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CADL shares will trade within this expected range on the day.